专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009107983A3 STABILIZED SINGLE-LIQUID PHARMACEUTICAL COMPOSITION CONTAINING DOCETAXEL 审中-公开
标题翻译：含有多西他赛的稳定的单一液体药物组合物
公开(公告)号：WO2009107983A3
公开(公告)日：2009-12-03
申请号：PCT/KR2009000911
申请日：2009-02-26
申请人： DONG A PHARM CO LTD , YOO MOO-HI , CHA BONG-JIN , KIM JEONG-HOON , JANG SUN-WOO , WON DONG-HAN
发明人： YOO MOO-HI , CHA BONG-JIN , KIM JEONG-HOON , JANG SUN-WOO , WON DONG-HAN
IPC分类号： A61K9/08 , A61K31/337 , A61K47/08 , A61P35/00
CPC分类号： A61K9/0019 , A61K47/26
摘要： The present invention relates to a liquid pharmaceutical composition for injection containing docetaxel. The composition of the present invention contains (A) docetaxel and a pharmaceutically acceptable salt, (B) a surface active agent selected from polysorbate, polyoxyethylene glycol ester and polyoxyethylene castor oil derivatives, (C) a solvent containing anhydrous ethanol in the range of concentration of 100 to 800mg/ml in an injection solution, and (D) a pH adjuster of the amount suitable for adjusting pH of the liquid composition to 5 or lower. The composition of the present invention can be directly diluted in a perfusion liquid even without using an intermediary dilute solution in cases where the composition of the present invention is used as injectable preparations as the composition is formed into a single liquid phase. Further, the composition of the present invention is suitable for effective injection of docetaxel as the pharmaceutical stability of the composition is significantly improved.
摘要翻译：本发明涉及含有多西他赛的注射用液体药物组合物。本发明的组合物含有（A）多西紫杉醇及其药学上可接受的盐，（B）选自聚山梨酸酯，聚氧乙烯乙二醇酯和聚氧乙烯蓖麻油衍生物的表面活性剂，（C）含有浓度范围的无水乙醇的溶剂（D）适于将液体组合物的pH调节至5或更低的量的pH调节剂。在本发明的组合物用作可注射制剂的情况下，即使不使用中间稀释溶液，本发明的组合物也可以在灌注液中直接稀释，因为组合物形成单一液相。此外，由于组合物的药物稳定性显着改善，本发明的组合物适合有效注射多西紫杉醇。

2. 发明专利

ZA201004462B STABILIZED SINGLE-LIQUID PHARMACEUTICAL COMPOSITION CONTAINING DOCETAXEL 未知
公开(公告)号：ZA201004462B
公开(公告)日：2011-04-28
申请号：ZA201004462
申请日：2010-06-24
申请人： DONG-A PHARM CO LTD
发明人： WON DONG-HAN , JANG SUN-WOO , KIM JEONG-HOON , CHA BONG-JIN , YOO MOO-HI
摘要： This invention relates to a single-liquid pharmaceutical composition for injection containing docetaxel. The composition includes (A) docetaxel and pharmaceutically acceptable salts thereof, (B) a surfactant selected from the group consisting of polysorbate, polyoxyethylene glycol ester and polyoxyethylene castor oil derivatives, (C) a solvent comprising anhydrous ethanol in a concentration range of 100 to 800 mg/ml, in an injectable solution, and (D) a pH adjuster of an amount suitable for adjusting the pH of the liquid composition to 5 or less. The composition may be directly diluted in a perfusion liquid even without the use of an intermediary dilute solution in case the composition is used for injectable preparations since the composition is in a single liquid phase. Furthermore, the composition is suitable for effective administration of docetaxel since the pharmaceutical stability of the composition is significantly improved.

3. 发明专利

TR201005726T2 未知
公开(公告)号：TR201005726T2
公开(公告)日：2011-10-21
申请号：TR201005726
申请日：2009-02-26
申请人： DONG A PHARM CO LTD
发明人： CHA BONG-JIN , YOO MOO-HI , JANG SUN-WOO , KIM JEONG-HOON , WON DONG-HAN
IPC分类号： A61K9/08 , A61K31/337 , A61K47/08 , A61P35/00
摘要： This invention relates to a single-liquid pharmaceutical composition for injection containing docetaxel. The composition includes (A) docetaxel and pharmaceutically acceptable salts thereof, (B) a surfactant selected from the group consisting of polysorbate, polyoxyethylene glycol ester and polyoxyethylene castor oil derivatives, (C) a solvent comprising anhydrous ethanol in a concentration range of 100 to 800 mg/ml, in an injectable solution, and (D) a pH adjuster of an amount suitable for adjusting the pH of the liquid composition to 5 or less. The composition may be directly diluted in a perfusion liquid even without the use of an intermediary dilute solution in case the composition is used for injectable preparations since the composition is in a single liquid phase. Furthermore, the composition is suitable for effective administration of docetaxel since the pharmaceutical stability of the composition is significantly improved.

4. 发明专利

CA2714942C STABILIZED SINGLE-LIQUID PHARMACEUTICAL COMPOSITION CONTAINING DOCETAXEL 未知
公开(公告)号：CA2714942C
公开(公告)日：2014-06-17
申请号：CA2714942
申请日：2009-02-26
申请人： DONG A PHARM CO LTD
发明人： YOO MOO-HI , CHA BONG-JIN , KIM JEONG-HOON , JANG SUN-WOO , WON DONG-HAN
IPC分类号： A61K9/08 , A61K31/337 , A61K47/08 , A61P35/00
摘要： This invention relates to a single-liquid pharmaceutical composition for injection containing docetaxel. The composition includes (A) docetaxel and pharmaceutically acceptable salts thereof, (B) a surfactant selected from the group consisting of polysorbate, polyoxyethylene glycol ester and polyoxyethylene castor oil derivatives, (C) a solvent comprising anhydrous ethanol in a concentration range of 100 to 800 mg/ml in an injectable solution, and (D) a pH adjuster of an amount suitable for adjusting the pH of the liquid composition to 5 or less. The composition may be directly diluted in a perfusion liquid even without the use of an intermediary dilute solution in case the composition is used for injectable preparations since the composition is in a single liquid phase. Furthermore, the composition is suitable for effective administration of docetaxel since the pharmaceutical stability of the composition is significantly improved.

5. 发明专利

AU2009217927B2 Stabilized single-liquid pharmaceutical composition containing docetaxel 未知
公开(公告)号：AU2009217927B2
公开(公告)日：2012-06-07
申请号：AU2009217927
申请日：2009-02-26
申请人： DONG A PHARM CO LTD
发明人： KIM JEONG-HOON , WON DONG-HAN , CHA BONG-JIN , JANG SUN-WOO , YOO MOO-HI
IPC分类号： A61K9/08 , A61K31/337 , A61K47/08 , A61P35/00
摘要： The present invention relates to a liquid pharmaceutical composition for injection containing docetaxel. The composition of the present invention contains (A) docetaxel and a pharmaceutically acceptable salt, (B) a surface active agent selected from polysorbate, polyoxyethylene glycol ester and polyoxyethylene castor oil derivatives, (C) a solvent containing anhydrous ethanol in the range of concentration of 100 to 800mg/ml in an injection solution, and (D) a pH adjuster of the amount suitable for adjusting pH of the liquid composition to 5 or lower. The composition of the present invention can be directly diluted in a perfusion liquid even without using an intermediary dilute solution in cases where the composition of the present invention is used as injectable preparations as the composition is formed into a single liquid phase. Further, the composition of the present invention is suitable for effective injection of docetaxel as the pharmaceutical stability of the composition is significantly improved.

6. 发明专利

AU2009217927A1 Stabilized single-liquid pharmaceutical composition containing docetaxel 未知
公开(公告)号：AU2009217927A1
公开(公告)日：2009-09-03
申请号：AU2009217927
申请日：2009-02-26
申请人： DONG A PHARM CO LTD
发明人： KIM JEONG-HOON , WON DONG-HAN , CHA BONG-JIN , JANG SUN-WOO , YOO MOO-HI
IPC分类号： A61K9/08 , A61K31/337 , A61K47/08 , A61P35/00
摘要： This invention relates to a single-liquid pharmaceutical composition for injection containing docetaxel. The composition includes (A) docetaxel and pharmaceutically acceptable salts thereof, (B) a surfactant selected from the group consisting of polysorbate, polyoxyethylene glycol ester and polyoxyethylene castor oil derivatives, (C) a solvent comprising anhydrous ethanol in a concentration range of 100 to 800 mg/ml, in an injectable solution, and (D) a pH adjuster of an amount suitable for adjusting the pH of the liquid composition to 5 or less. The composition may be directly diluted in a perfusion liquid even without the use of an intermediary dilute solution in case the composition is used for injectable preparations since the composition is in a single liquid phase. Furthermore, the composition is suitable for effective administration of docetaxel since the pharmaceutical stability of the composition is significantly improved.

7. 发明专利

NZ587578A STABILIZED SINGLE-LIQUID PHARMACEUTICAL COMPOSITION CONTAINING DOCETAXEL 未知
公开(公告)号：NZ587578A
公开(公告)日：2012-08-31
申请号：NZ58757809
申请日：2009-02-26
申请人： DONG A PHARM CO LTD
发明人： CHA BONG-JIN , KIM JEONG-HOON , YOO MOO-HI , JANG SUN-WOO , WON DONG-HAN
IPC分类号： A61K9/08 , A61P35/00 , A61K31/337 , A61K47/08 , C07D305/14
摘要： Disclosed is a single-liquid pharmaceutical composition for injection containing docetaxel (formula 1) controlled in a pH range of 3.0 to 5.0, consisting of (A) docetaxel or pharmaceutically acceptable salts thereof; (B) a surfactant selected from the group consisting of polysorbate, polyoxyethylene glycol ester and polyoxyethylene castor oil derivatives; (C) an anhydrous ethanol in a concentration range of 100 to 800 mglml; and (D) a pH adjustor selected from the group consisting of citric acid, fumaric acid, lactic acid, stannic acid, succinic acid, maleic acid, acetic acid, tartaric acid, and phosphoric acid.

8. 发明专利

MX2010009031A COMPOSICION FARMACEUTICA DE UN SOLO LIQUIDO ESTABILIZADA QUE CONTIENE DOCETAXEL. 未知
公开(公告)号：MX2010009031A
公开(公告)日：2010-09-10
申请号：MX2010009031
申请日：2009-02-26
申请人： DONG A PHARM CO LTD
发明人： YOO MOO-HI , CHA BONG-JIN , KIM JEONG-HOON , JANG SUN-WOO , WON DONG-HAN
IPC分类号： A61K9/08 , A61K31/337 , A61K47/08 , A61P35/00
摘要： Esta invención se relaciona a una composición farmacéutica de un solo líquido para inyección que contiene docetaxel. La composición incluye (A) docetaxel y sales farmacéuticamente aceptables del mismo, (B) un surfactante seleccionado del grupo que consiste de polysorbate, éster de polioxietilenglicol y derivados de aceite de ricino de polioxietileno, (C) un solvente que comprende etanol anhidro en un intervalo de concentración de 100 a 800 mg/Ml en una solución inyectable, y (D) un ajustador de pH de una cantidad adecuada para ajustar el pH de la composición líquida a 5 o menos. La composición puede ser directamente diluida en un líquido de perfusión aun sin el uso de una solución diluida intermediaria en caso de que la composición sea utilizada para las preparaciones inyectables puesto que la composición está en una fase de un solo líquido. Además, la composición es adecuada para la administración efectiva de docetaxel puesto que la estabilidad farmacéutica de la composición es significantemente mejorada.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式